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262 M. Hasan et al.Automation highlighting the standardized and automated procedures used for immunophenotyping of human;
Standardization whole blood samples. We optimized eight-color antibody panels and procedures for staining and lysisof whole blood samples, and implemented pre-analytic stepswith a semi-automatedworkflow using a
robotic system. We report on four panels that were designed to enumerate and phenotype major
immune cell populations (PMN, T, B, NK cells, monocytes and DC). This work establishes a
foundation for defining reference values in healthy donors. Our approach provides robust protocols
for affordable, semi-automated eight-color cytometric immunophenotyping that can be used in
population-based studies and clinical trial settings.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Multiparametric flow cytometry is widely used for pheno-
typing immune cell populations in human blood samples.
The abundance of reagents and growing technical innova-
tions in the field of cytometry (e.g., mass cytometry, imaging
cytometry and spectral analyzers) has further enhanced the
enthusiasm for applying these approaches to the management
of patients and the phenotyping of healthy individuals. Flow
cytometric techniques have been used for more than two
decades in clinical laboratories for the enumeration of CD4+
and CD8+ T cells, in the diagnosis of AIDS [1,2], and also in the
characterization of lymphoma and leukemic immune cell
expansions [3,4]. However, the implementation of standard-
ized procedures within academic research laboratories has
recently become a concern for the community, as the absence
of such standardization has precluded comparison between
studies and experimental settings. Indeed, greater attention
is now placed on the requirement for optimized approaches
and harmonization of methods [5,6]. Several international
initiatives have supported increased standardization of flow
cytometry protocols and applications across multiple labora-
tories that share common scientific or clinical interests. These
include the EuroFlow Consortium, which focuses on laboratory
procedures for the phenotyping of malignant leukocytes
[7,8]; the Human Immunology Project Consortium (HIPC)
and European Network for Translational Immunology Re-
search and Education (ENTIRE), which are working together
to develop panels for the phenotyping healthy donors [5,6,9];
the ONE study consortium, which is addressing cellular
phenotyping in the setting of transplantation [10]; and the
Association for Cancer Immunotherapy (CIMT), which have
established proficiency panels for different cell populations
[11].
The reproducibility of cytometric data depends on five
principle criteria: sample type, sample handling, choice of
reagents, instrument selection and qualification, and data
analysis. In three coordinated reports, we detail the steps that
have been taken by theMilieu Intérieur Consortium to control
for the pre-analytic aspects of cellular phenotyping (reported
here), to optimize the analysis of multi-dimensional data
[Chen et al. co-submission], which applied together have
allowed the characterization of immune phenotype variation
in a population of healthy donors [Urrutia et al., in prepara-
tion]. Our approach to immune cell phenotyping supports our
Consortium's long-term efforts in utilizing cytometric data as a
quantitative intermediate phenotype for association studies.Only with accurate and reproducible methodologies can we
begin to establish, integrate and share large data-warehouses
of phenotypic and genetic data.
Several prior and ongoing efforts have contributed to the
challenge of harmonizing methods in academic research
laboratories. Particular attention has been given to sample
type, with comparative assessments of fresh or frozen
purified peripheral blood mononuclear cells (PBMCs) and
whole blood [12–14]. Additional parameters that have been
considered include panel design [6,8,10], the use of liquid,
lyophilized or freeze-dried reagents [15] and the calibration
and settings for the optical bench of multi-laser cytometers
that permit longitudinal, multi-user or inter-laboratory
standardization [7]. In academic studies, however, there is
less attention given to the variability introduced by sample
handling. In many instances, sample collection is not proximal
to core facilities and despite the use of standard operating
procedures (SOPs), studies have not evaluated the impact of
manual sample handling on the measured cellular phenotypes
such as size, granularity and activation state.
In this report, we detail the steps that were taken to
establish a robust protocol for immunophenotyping from
100 μl of fresh whole blood, using four eight-color cytom-
etry panels. We present the design of cytometry panels
used for phenotyping and quantifying major cell populations
present in human blood — T cells, B cells, NK cells, monocytes,
dendritic cells, neutrophils, basophils and eosinophils. These
data establish the foundation for the analysis of six hundred
healthy donors, analyzed over a six-month time interval.2. Materials and methods
2.1. Human subject materials, reagents and instru-
mentation used
For optimization studies and panel development, whole blood
samples were collected from healthy volunteers enrolled at
the Institut Pasteur Platform for Clinical Investigation and
Access to Research Bioresources (ICAReB) within the
Diagmicoll cohort. The biobank activity of ICAReB platform is
NF S96-900 certified. The Diagmicoll protocol was approved by
the French Ethical Committee (CPP) Ile-de-France I, and the
related biospecimen collection was declared to the Research
Ministry under the code N° DC 2008-68. Samples collected as
part of the Milieu Intérieur population based study were
procured by investigators working at BioTrial, Rennes [Thomas
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established in order to ensure temperature controlled delivery
to Institut Pasteur, Paris within 6 h of blood draw (Supple-
mentary Protocol #1). In all cases, whole blood was collected
using Li-heparin as an anti-coagulant and maintained at room
temperature (18–25°) until processing. The cells were
stained using commercially available monoclonal antibodies
(Table S1), according to the operating procedure developed
as described herein. The standardized protocol is provided
(Supplementary Protocol #2). We evaluated three red blood
cell lysis reagents to optimize the staining protocol: BD
FACS lysing solution (BD Biosciences, ref. 349202), Red
Blood Cell lysis (Miltenyi Biosciences, ref. 130-094-183) and
RBC lysis buffer (eBioscience Inc., ref. 00-4333-57). Fc-receptor
blocking antibodies were used (eBioscience ref. 14-9161).
Dead cells were excluded using the Fixable Viability Dye
(FVD) eFluor 506 (eBioscience, ref. 65-0866) in the PMN and
DC panels. For establishing compensation matrices, Mouse
(BD CompBead Set Anti-mouse Ig, k ref. 552843) and Rat (BD
CompBead Set Anti-rat/hamster Ig, k ref. 552845) compen-
sation beads were employed. The acquisition of cells was
performed using two MACSQuant analyzers (Serial numbers
2420 & 2416), each fit with identical three lasers and ten
detector (FSC, SSC and eight fluorochrome channels) optical
racks. Calibration of instruments was performed using
MacsQuant calibration beads (Miltenyi, ref. 130-093-607). The
semi-automated staining was performed using the Evo-150
liquid handling system (Tecan). A detailed script for the
semi-automated sample processing is provided in (Online
Supplementary Data File #1, http://www.milieuinterieur.
fr/en).
2.2. Staining protocol for cytometric analysis
Whole blood (2 mL) was washed by mixing fresh whole blood
and PBS at a 1:1 ratio, followed by centrifugation at 500g for
5 min at 18–22 °C (room temperature). Washed blood and
pre-mixed liquid reagents were loaded onto the Freedom
Evo 150 liquid handling system. The supernatant was
aspirated and discarded, followed by the addition of fresh
PBS taking it to the same final volume as input whole blood.
Antibody premixes were prepared, shortly spun (about 20 s)
and 100 μl of the resuspended cells was aliquoted into tubes
containing the pre-mixed antibody cocktail. The samples
were shortly vortexed and incubated 20 min in the dark at
room temperature (RT). In samples stained with the PMN and
DC panels 1 mL of 1x viability dye solution was added,
followed by incubation for 30 min in the dark at 4 °C.
Thereafter, 1 ml of cold PBS (4 °C) was added to the tubes,
which were centrifuged for 5 min at 500g and the superna-
tant was aspirated. All samples, irrespective of the panel
used, were resuspended in 2000 μl of 1x RBC lysing solution,
shortly vortexed and incubated 15 min at RT protected from
light. After centrifugation for 5 min at 500g, the supernatant
was aspirated, the samples were resuspended in 240 μl PBS
and immediately acquired on the cytometer.
2.3. Data analysis and statistical methods
Flow cytometry data were generated using MACSQuantify™
software version 2.4.1229.1 and saved as .mqd files(Miltenyi). The files were converted to FCS compatible
format and analyzed by FlowJo software version 9.5.3.
Statistical graphs were prepared with the R Software version
3.0.1 (Ref.: R Core Team (2013). R: A language and
environment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria. URL http://www.R-
project.org/), using the ggplot2 graphical package version
0.9.3.1 [16].3. Results
3.1. Panel design
To enable detection, enumeration and phenotyping of major
leukocyte populations present in circulation — PMNs, T cell,
B cells, NK cells, monocytes and DCs — we designed four
8-color cytometry panels. The “lineage” panel covered the
major cell populations, providing a reference for comparison
with other consortia and served as an internal control for
other panels (Fig. 1A). The “PMN” panel enabled the
classification of neutrophils (CD16+FcεRIα− cells), basophils
(FcεRIα+CD16−) and eosinophils (CDw125+) (Fig. 1B). Activa-
tion status of neutrophils was assessed by CD62L expression,
and used as a marker of healthy donor status. The “T cell”
panel was designed to classify CD4+ and CD8+ naïve (Tnaive),
central memory (TCM), effector memory (TEM) and EMRA+ T
cell (TEMRA) subsets, utilizing the relative expression levels
of CD27, CD45RA and CCR7 (Fig. 1C) [17]. By combining
anti-CD8α and anti-CD8β antibodies within the same panel,
we were able to distinguish CD8αα, CD8αβ and CD4 CD8αα T
cells [18] (Fig. 1C). Information on the activation status of T
cells was obtained by surface expression of HLA-DR. The
“DC” panel delineates three principle subsets of dendritic
cells in peripheral blood: plasmacytoid dendritic cells (pDCs),
BDCA-1+ and BDCA-3+ conventional dendritic cells (herein
referred to as cDC1 and cDC3, respectively) (Fig. 1D).3.2. Selection of reagents and optimization of semi-
automated staining procedure
Careful selection of antibody clones and optimal combinations
of compatible fluorochromes is key to establish robust flow
cytometry panels. We worked with three antibody suppliers
(BD Biosciences, eBioscience and Miltenyi), who provided us
with several clones and fluorochrome combinations for each
antigen of interest. As previously reported by others [6],
significant differences were observed between the different
reagents despite their targeting the same cell surface protein.
Our selection criteria were (i) specificity of the signal, as
based on the staining index that is defined as the difference
between the positive and the negative populations and the
spread of the negative population [19]; (ii) signal resolution;
(iii) availability of desired fluorochrome; (iv) fluorochrome
stability (tandemdyes); (v) price and availability of single lot of
reagents for cohort study; and, when possible, (vi) availability
of CE-IVD format. A complete list of tested antibodies and
notable observations concerning their staining performance
are reported in Table S1. Two examples (anti CD14 and anti
CD8β) are shown to illustrate our testing and selection
procedures (Figure S1).
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Figure 1 Organization of panels for whole blood immunophenotyping. Four eight-color panels were established in order to quantify
and characterize the major leukocyte populations in circulation. (A) The lineage panel consisted of markers for T cell, B cell, NK cell and
monocyte populations. (B) The polymorphonuclear cells (PMN) permitted classification of neutrophils, basophils and eosinophils. (C) The
T cell panel assessed CD4+ and CD8+ naïve, central memory (Tcm), effector memory (TEM) and effector memory RA
+ (TEMRA) subsets. (D)
The dendritic cell (DC) panel classified the three major DC subsets— pDCs, cDC1 and cDC3. Selection of fluorochrome, clone, vendor and
optimal dilution for 100 μl of whole blood used in the study is indicated. FVD, fixed viability dye, was used at a 1:1000 dilution.
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3.3.1. The lineage panel
For the characterization of major leukocyte populations,
we first identified CD45+ hematopoietic cells, followed by
exclusion of doublets (Fig. 2A). Subsequently, B cells were
gated as CD19+CD16−, and T cells were identified as CD19−
cells followed by CD3+ staining, then analyzed for the
expression of CD4 and CD8 (Fig. 2B). Within the CD3− cells,
NK cells were identified as CD56+ and analyzed for their
expression of CD16 and CD56. In the population of CD56−
cells, CD16hiSSClow cells were selected in order to segregate
monocytes from neutrophils. Further gating identified
CD14+CD16int monocytes and CD14lowCD16hi monocytes.
Neutrophils were defined as CD16hiSSChi (Fig. 2B).
3.3.2. The PMN panel
To characterize granulocytes populations, doublets were
first excluded (Fig. 3A) and neutrophils were identified asCD16hiCDw125− live cells. We also assessed the expression of
CD62L within this cell population as a marker of activation
(Fig. 3B). Basophils and eosinophils were gated within the
CD16low/− cells as FcεRIα+CD203c+ and CDw125+, respective-
ly (Fig. 3C). Of note, we highlight a difference in the staining
of different subpopulations of PMN for Fixable Viability Dye
(FVD) (Fig. 3A–C), using saponin treated cells as a positive
control for dead cells (Fig. 3D).
3.3.3. The T cell panel
T cells were identified as CD3+ cells (Fig. 4A). Upon
exclusion of doublets (Fig. 4A), CD4+ and CD8β+ were gated
and analyzed. We characterized naïve (TN), central memory
(TCM), effector memory (TEM) and effector memory express-
ing RA (TEMRA) subpopulations of both T cell subsets, based
on their expression of CD45RA and CD27 [17,20] (Fig. 4B). TN
and TCM cells have also been defined by the expression of
CCR7 [21]. We therefore assessed the expression of CCR7 by
these cell populations. The activation status was determined
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Figure 2 Gating strategy for the lineage panel. (A) CD45+ cells were identified. Doublets were excluded using forward scatter
height (FSC-H) and forward scatter width (FSC-W) followed by side scatter height (SSC-H) and side scatter area (SSC-A). (B) Expression
of CD19 (red gate) was used to identify B cells. T cells were identified within the CD19− cells based on CD3 expression (green gate) and
analyzed for the expression of CD4 and CD8β. Within the CD3− cells (blue gate), NK cells were identified as CD56+ and analyzed for
their expression of CD16 and CD56. In the population of CD56− cells, CD14+ and CD16+ monocytes were gated within the CD16+/low
SSClow cells (violet gates). Finally, neutrophils were identified as CD16+SSChi (orange gate).
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267Standardized flow cytometry procedures for whole blood immunophenotypingby HLA-DR expression. In addition, the CD4+ T cell popula-
tion expressing CD8αα was identified (Fig. 4B).3.3.4. The DC panel
To characterize DCs, we first gated on HLA-DR+CD14− and
excluded dead cell doublets, and CD3+, CD19+ or CD14+
lineage positive cells using a cocktail of reagents (Fig. 5A).
pDC, cDC1 and cDC3 populations were identified as
BDCA4+BDCA2+ (CD304+CD303+), BDCA1+ (CD1c+) and
BDCA3+ (CD141+), respectively (Fig. 5B). The activation
status of the three DC subsets was assessed by their
expression of HLA-DR and the costimulatory molecule CD86
(Fig. 5C). The position of gates to define cDC subsets was
determined using HLA-DR−CD14− cells as a negative control
(Fig. 5D).
3.4. Standard operating procedures
To optimize the pre-analytical steps of immunophenotyping,
we evaluated different conditions for each step of the protocol
(Supplementary Protocol #2). We focused in particular on the
temperature and duration of blood storage, as well as on red
blood cell lysis and the staining protocol. Finally, to make the
procedure amenable to a large cohort study, we implemented
a semi-automated procedure using liquid handling robotics.3.4.1. Sample
The treatment of blood samples has a large impact on
cytometry data [15]. One of the biggest considerations was
analysis of fresh blood as compared to freezing samples and
batching analysis. To assess potential differences in results
obtained by immunophenotyping of fresh whole blood versus
thawed PBMC in our experimental conditions, we compared
results from eighteen healthy donors. We did not observe a
major difference in B cell frequencies (Figure S2A, upper
panel) or of CD19 mean fluorescence intensity (MFI) values
(Figure S2A, lower panel). Lower frequencies of CD3+
lymphocytes and a significantly lower expression level of
CD3 were observed in frozen/thawed PBMCs compared to
whole blood (Figure S2A). While the frequency of CD4+ and
CD8+ lymphocytes was similar in thawed PBMC and whole
blood (Figure S2A, upper panels), we noted higher and more
variable MFI values of CD4, and lower expression of CD8β in
PBMCs as compared to fresh whole blood samples (Figure
S2B, lower panels). Analysis of thawed PBMCs revealed lower
CD56 expression, but no alteration in frequencies of NK cells
(Figure S2B). Other differences were also noted, again with
the observation that freeze/thaw introduced variance,
especially in monocyte and DC populations (Figure S2C and
S2D, lower panels). Based on these data, and the experienceFigure 3 Gating strategy for the PMN panel. (A) Doublets were e
parameters. (B) Neutrophils were identified based on their high exp
cells with low levels of CDw125 expression, low levels of FVD and hi
valuated for high FcεRIα expression and intermediate CD203c expr
intermediate expression of CDw125 and CD16 (red gate), hallmarks o
1 min, washed with PBS and stained with FVD. Granulocytes and ly
different levels of auto-fluorescence of lymphocytes and granulocytof other consortia [4,6], we utilized fresh whole blood
samples for our study.
To assess the impact of time between blood draw and
staining, we analyzed blood from three healthy donors at
four different time-points: immediately after blood draw,
and 2 h, 7 h and 24 h post-blood draw. The aliquots were
kept at room temperature (18–25 °C) until the analysis.
Staining patterns of the analyzed immune cell populations
did not change within the first 7 h. However, further delay
in time of sample staining and analysis (24 h) had a non-
negligible impact on the size and granularity of cells, with an
additional population of FCShigh/SSClow cells appearing 24 h
after collection (Fig. 6). Furthermore, there was a striking
impact on the activation status of dendritic cells after 24 h,
as observed by an increased expression of HLA-DR on the
surface of cDC3 cells (Fig. 6).
We also evaluated the impact of the time between
sample collection and processing on the cell numbers of
selected immune populations. No differences were observed
in the T cell, B cell, neutrophil or dendritic cell numbers
(Fig. 7). The notable exception was the number of
neutrophils in one of the three donors. Together, our data,
based on cell phenotyping and enumeration studies, clearly
showed that 6 h post-blood draw is the maximum permitted
delay.
3.4.2. Staining protocol
Fresh whole blood samples were washed to eliminate
soluble antibodies and other molecules that may interfere
with staining. The duration of antibody incubation and
staining temperature was evaluated (data not shown). Since
blocking of FcR did not have a significant impact on the
results (data not shown), it was not included in the staining
protocol. The staining was followed by red blood cell lysis.
We tested three red blood cell lysis solutions and identified
the BD solution to be the most efficient, with reagents from
other suppliers being either less efficient (Miltenyi) or
slower in achieving RBC lysis (eBioscience) (data not
shown). Additionally, we tested different criteria that
impact lysis conditions and the reproducibility of the results:
duration of incubation in lysis solution, use of mixing and the
implementation of a wash step. We highlight that an
additional wash step was introduced after red blood cell
lysis to ensure complete elimination of the lysis solution,
which also showed better preservation of size and granular-
ity characteristics of leukocytes. The staining protocol,
established for immunophenotyping of 100 μl of fresh
whole blood, is detailed in Supplementary Protocol #2. All
tested antibodies were titrated to fit the experimental
conditions described in the protocol. To minimize variation
of fluorescent signal intensity, only one lot of each antibody
was used for staining throughout the whole study.xcluded from the analysis using FSC-W/FSC-H and SSC-A/SSC-H
ression of CD16 (green gate), with hierarchical gating to select
gh expression of CD62L. (C) CD16low/− cells were independently
ession (blue gate), a phenotype characteristic of basophils; or
f eosinophils. (D) Whole blood was incubated with 1% saponin for
mphocytes were gated based on their size and granularity. The
es used to set the gates in (B) and (C) are shown.
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268 M. Hasan et al.While we were finalizing our study a comprehensive report
by Kalina et al. described the efforts of the EuroflowConsortium
to standardize cytometry protocols. We noted that ourindependently established procedures were very similar to the
ones described by Kalina et al. and further emphasized the
importance of reagent selection and staining conditions [7].
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All clinical laboratory tests use automation in sample
processing and attempts have been made to implement
automation in genomic assays (DNA/RNA extractions,
genotyping, microarray assays, etc.). We decided to take
advantage of automation in sample preparation for cellular
immunophenotyping. To achieve this, we implemented our
protocol using the EVO150 liquid handling platform (Tecan).
The premix of antibodies was prepared manually on a daily
basis, and all other steps for the staining protocol were
performed using the liquid handling platform, with the
exception of centrifugation. The pipetting scripts for the
platform were created to enable staining of 4 to 12 samples,
in parallel, in 96-deep well plates (Online Supplementary
Data File #1, http://www.milieuinterieur.fr/en).3.4.4. Setting of pre-acquisition parameters
Our study complies with the MIFlowCyt requirements
[22]. Dead cells were excluded using FVD in the PMN and
DC panels, in which either rare populations needed to be
identified, or a high autofluorescence of target cells was
expected. A dump channel was included in the DC panel to
exclude CD19+, CD3+, NKp46+, or CD14+ cells to further improve
specificity, and in accordance to prior studies [23]. For
antibodies that showed weak signals and did not enable
clear separation of positive from negative cell populations
(e.g., CCR7), we used FMO (fluorescenceminus one) staining to
set the positive/negative cell gates. During the first two
months of the study, compensation controls were run every
day, using automatic hardware compensation on MACSQuant.
The compensation beads were used to calculate the
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270 M. Hasan et al.compensation matrix for all antibodies, except for those
labeled with Horizon V500 (BD) and dead cell marker
(FVD eF506, eBio). For these reagents, cells were used as
recommended by the suppliers. Consistent with EuroFlow
consortium results [7], our compensation matrices did notchange (PMT values varied b+/−5 V, data not shown). We
thus decided to run compensation controls bi-weekly, unless
the PMT voltage values reported by the cytometer after the
daily set-up varied for N+/−5 V from the values obtained
during the prior compensation run. In order to control for
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271Standardized flow cytometry procedures for whole blood immunophenotypingcross-contamination, samples were plated with PBS filling
every other well in the 96-well plates. None of the negative
wells showed positive cells for any of the four panels (not
shown).
3.4.5. Cytometer
Initial testing of panels was performed using an LSRII
cytometer (BD) equipped with 4 lasers (488 nm, 405 nm and
630 nm and 658 nm). The design of our study (four 8-colorcytometry panels) required an instrument that enables auto-
matic acquisition from 96-well plates, the acquisition of
absolute cell counts and at least 3-lasers. We compared two
cytometers that corresponded to these criteria and that were
commercially available at the beginning of the study (initiated
in 2012): the BD FACSVerse and Miltenyi MACSQuant. The
cytometers were evaluated based on their hardware, sample
acquisition performance, software robustness, quality control
and post-installation support provided by the suppliers
Table 1 Test of repeatability — technical replicates ⁎.
Cell type Parameter Stat Panel Donor
1 2 3 4 5 6
T cells CD3+ Median (CV) T 1019 (9.2) 527 (14.4) 271 (9.2) 537 (5.8) 736 (13.0) 623 (4.1)
Lin 1020 (9.8) 530 (09.0) 260 (4.0) 536 (4.2) 694 (09.7) 603 (3.9)
CD8+ Median (CV) T 165 (9.0) 127 (14.7) 66 (8.1) 194 (6.2) 149 (14.9) 151 (5.6)
Lin 175 (9.8) 135 (10.1) 63 (3.8) 209 (3.9) 157 (09.8) 160 (4.0)
CD4+ Median (CV) T 768 (14.6) 359 (14.6) 170 (9.5) 768 (5.7) 516 (14.3) 347 (4.1)
Lin 757 (09.6) 357 (08.3) 161 (4.1) 284 (4.5) 473 (09.6) 413 (3.9)
Monocytes CD14+ Median (CV) Lin 334 (10.0) 96 (16.1) 216 (02.7) 220 (3.5) 284 (11.3) 149 (7.8)
DC 283 (06.4) 85 (16.3) 228 (10.5) 227 (7.6) 154 (22.9) 144 (7.4)
DC pDC Median (CV) DC 3 (09.9) 2 (15.2) 2 (8.7) 5 (11.2) 4 (21.5) 2 (11.8)
NK cells CD56+ Median (CV) Lin 152 (11.1) 95 (10.9) 96 (5.1) 122 (04.2) 142 (10.4) 100 (03.4)
Granulocytes Neutrophils Median (CV) Lin 2040 (4.4) 650 (11.1) 797 (6.2) 1060 (7.1) 1770 (06.0) 1590 (5.8)
PMN 2652 (6.3) 1247 (08.4) 1135 (3.0) 1643 (5.5) 2052 (10.3) 1802 (7.4)
⁎ Fresh blood samples from six healthy donors were divided in five aliquots each and immediately stained. Shown are absolute cell
numbers (median value) of selected cell populations per 1 μl of blood. For each immune cell population identified, the intra-panel
coefficient of variation (CV) was calculated. In instances where cell populations could be identified by two different panels, both data are
reported. The cell numbers of each indicated cell population obtained by PMN, T and DC panels were calculated upon normalization of the
total cell number obtained by each panel to the total cell number as quantified by the lineage (Lin) panel.
272 M. Hasan et al.(Supplementary Table 2). Although the hardware characteris-
tics, quality control and the concept of the software were
comparable between the two systems, MACSQuant showed
significant advantages concerning the software robustness and
performance. In addition, its cell counting feature was
reproducible and easy to assess. The MACSQuant's SOP requires
a daily quality control check using control beads to monitor the
performance of instrument. The cytometer enables identifica-
tion of “bank settings” for up to 5 different panels. These
settings store the target values of MFI for five combinations of
up to eight antibodies/fluorochromes (5 eight-color panels). On
each occasion that the control beads are run the system
automatically sets the PMT values so that the intensity of signal
matches predefined MFI values, and thus overcomes fluctua-
tions or decrease of laser power ensuring data reproducibility.
Two MACSQuant cytometers were installed with a distinct bank
settings programmed on the instruments for the panels used in
the study.3.5. Data analysis
We selected the FlowJo software to analyze data. In order to
improve standardization of analysis, we created analysisFigure 8 Repeatability studies, longitudinal studies and panel-t
samples from six individual donors were divided in five aliquots for
semi-automated procedures. The immune cell populations were iden
gating strategies. The graphs show inter-panel comparison of the
(lineage vs. DC panel, lineage vs. T cell and lineage vs. PMN panel).
for a given donor. Data from individual donors are represented by dis
obtained by two panels is indicated. (B, C) Stabilized human blood sa
Cells were stained using the lineage panel cocktail and labeled by t
(B) and absolute cell counts per μl of blood (C) are shown for the in
manufacturer on BD and Beckman Coulter flow cytometers is indic
indicated for each analyzed immune cell population. (D) Whole bloo
by the lineage panel cocktail using the semi-automated procedure. Se
over five months. Each dot represents the absolute cell number of in
are represented by distinct colors.templates for each panel. A template consists of the gating
strategy specific for the given panel, including a pre-defined
table with parameters selected for statistical analysis.
Magnetic gates were applied for the brightest and most
clearly defined antigens to minimize bias introduced by
manual repositioning of gates. Identical gate coordinates
were selected to gate on the same cell populations across
the four panels. The results obtained for each of the samples
were verified by an operator prior to final validation. In
order to minimize bias introduced by subjective analysis by
different individuals, a given panel was analyzed by the
same individual for all samples. The statistical parameters
selected for the analysis included absolute cell number of
each cell population of interest, its percentage in respect to
relevant parent populations, gate coordinates to monitor
fluorescence intensity and spread of fluorescent signal, and
MFI values for cell populations in which activation markers
were included (e.g., HLA-DR, CD86).
The bank settings programmed on the selected
cytometers enable standardization of fluorescent signal,
but do not enable standardization of cell size or granularity,
features that vary based on sample handling (Supplementary
Fig. 3). In order to take advantage of the standardization
procedures of the newest cytometers, we omitted theo-panel correlations illustrate assay stability. (A) Fresh blood
repeatability study each and immediately stained using defined
tified and absolute cell numbers obtained using above-indicated
indicated cell populations as obtained by two different panels
Each dot represents the median value of the five replicate tests
tinct colors. Standard deviation (SD) between the median values
mples (Eurocell) were analyzed in six independent experiments.
he semi-automated procedure. The percentages of lymphocytes
dicated cell subsets. The target value range determined by the
ated by the red triangles. The CVs for serial measurements are
d samples from six individual donors were collected and stained
rial measurements were performed at five different time-points
dicated cell types during serial measurements. Individual donors
273Standardized flow cytometry procedures for whole blood immunophenotypingtypical starting gates of FSC/SSC, and directly queried
fluorescent markers, using FSC/SSC when needed to exclude
doublets or dead cells (Figs. 2–5). The FlowJo templates
created for and used in the study are provided (Online
Supplementary Data File #2, http://www.milieuinterieur.
fr/en).D
2000
1500
0
1000
500
CD
3+
 T
 c
el
ls
 (#
/μ
l)
1000
750
0
500
250
CD
19
+
 B
 c
e
lls
 (#
/μ
l)
2000
1500
0
1000
500
CD
4+
 T
 c
el
ls
 (#
/ μ
l)
200
150
0
100
50
CD
56
+
 N
K 
ce
lls
 (#
/μl
)
1 2 3 4 5 1 2
Serial 
measurements
S
meas
250
A
1000
800
200
600
400
LineageT cell
CD
3+
 T
 c
el
ls
 (#
/μ
l) 800
200
600
400
T cell Line
CD
4+
 T
 c
el
ls
 (#
/ μ
l)
100
150
200
50
T cell Lineage
CD
8β
+
 T
 c
el
ls
 (#
/μ
l)
300
250
100
200
150
DCLineage
CD
14
+
 m
o
n
o
cy
te
s 
(#/
μl
)
3:1
4:1
2:1
T cell Line
CD
4+
 : 
CD
8β
+
(ra
tio
)
Lineage
2500
2000
1500
1000
PM
CD
16
+
n
e
u
tro
ph
ils
 (#
/μ
l)3.6. Assay validation: technical replicates and
robustness of the staining proceduresTo define the variance in our immunophenotyping proce-
dures, we performed experiments to assess repeatability%
 o
f l
ym
ph
oc
yt
es
B
CD
3+
CD
4+
CD
8+
CD
19
+
CD
16
+
NK
ce
lls
0
20
40
60
80
100
C
ce
ll 
nu
m
be
r/1
μL
CD
3+
CD
4+
CD
8+
CD
19
+
CD
16
+
NK
ce
lls
10
100
1000
4:1
3:1
1:2
2:1
1:1
CD
4+
 : 
CD
8β
+
(ra
tio
)
500
400
0
300
100
CD
14
+
  
m
o
n
o
cy
te
s 
(#/
μl
)
5:1
3 4 5 1 2 3 4 5
erial 
urements
Serial 
measurements
200
age
age
N
4.6% 3.4% 2.1% 2.0% 3.9%
5.0% 5.3% 5.1% 3.7% 5.0%
274 M. Hasan et al.and reproducibility. To assess repeatability, we analyzed the
same sample, in independent runs, by a single operator and
run on a single cytometer. In our experimental setting, fresh
blood samples from six healthy donors were separated into
five aliquots and stained using each of the four panels and
run on the liquid handling platform, followed by acquisition
on the corresponding MACSQuant cytometer. The results
were highly reproducible, with intra-panel CVs below 15% for
most of the analyzed cell subsets, irrespective of their
absolute counts (Table 1). Higher CVs were observed
for pDCs in one of the six donors (21.5%) and for CD14+
monocytes in two panels in two donors (16% and 23%). The
higher variance observed for monocytes may result from the
fact that CD14 can be expressed on other cell types, such as
neutrophils [24].
Most of the immune cell populations (CD3+, CD4+, CD8+ T
cells, CD14+ monocytes) were assessed independently using
twodifferent panels, and as such cross-panel comparisons were
possible (Table 1 and Fig. 8A). We normalized the total cell
counts of PMN, DC and T cell panels to those obtained by the
lineage panel because it identifies all “core” cell populations
and does not include an additional washing step that was used
during the staining of dead cells in PMN and DC panels.
To assess reproducibility, we evaluated the stability of
staining over time, an important consideration for large
cohort studies. To provide a stable reference, we utilized
commercially available stabilized blood, analyzed over a
period of one month. These data showed reproducible
results with CVs in the range of 2.0–5.3% (Fig. 8B and C).
The percentage of each analyzed cell population was within
the range of values indicated by the manufacturer (Fig. 8B).
The total cell numbers obtained, however, were under the
expected value, and consequently so were the total numbers
of each analyzed cell populations (Fig. 8C). This difference
may be explained by additional washing steps included in our
protocol, which are not used to set the reference values
indicated by the supplier of the stabilized blood. Another
factor contributing to the difference may be the utilization
of different cytometric platforms or the use of beads for cell
enumeration, as compared to a volume based calibrator
built into the cytometer itself. Finally, we analyzed blood
samples from six donors across five different time points. As
shown in Fig. 8D, the counts of most cell populations were
stable over time. The differences observed for NK and
monocyte cell number may be due to biological variation and
intra-individual variance can be factored into the interpre-
tation of our future population-based results.
4. Discussion
Delivering on the promise of personalized medicine requires
tools and techniques that allow both robust and reliable
assessment of the immune status of individuals and compar-
isons between studies. Specifically, the adoption of univer-
sal, robust cytometric protocols will allow cross-population
comparisons and the evaluation of the extent to which the
proportion of different cell populations in patients present-
ing immunopathology deviate from “healthy” expectations.
Flow cytometry is likely to play a key role due to recent
technological advances in instrument design, and the
availability of a large arsenal of reagents targeting specific
molecules. Indeed, these two factors now permit low-cost,real-time and deep phenotyping of immune cell popula-
tions. A notable concern for comparative studies is the
pre-analytic variation (sample processing, reagent selec-
tion, and instrument parameters). Although several inter-
national consortia have begun to tackle this issue, additional
efforts need to be taken in order to establish flow cytometry
as a tool applicable in routine clinical laboratories.
We report our advances in standardizing pre-analytic
procedures for flow cytometry for the Milieu Intérieur
Consortium, a single-center study aiming to defining reference
values of immune parameters in healthy individuals. Our
challenge was to establish a standardized procedure for flow
cytometry allowing the analysis of 15,000 samples by one
operator in a single center. In this context, we considered
automation as a solution to facilitate the workflow and to
standardize the pre-analytic procedures for flow cytometry.
Since clinical studies with large sample numbers involve
repetitive work, implementation of automated procedures
also eliminates possible error or variation caused by fatigued
technical personnel. Perhaps most importantly, an automated
procedure allows full traceability at each step (e.g., distribution
of antibodies, wash solutions). This is of particular importance if
flow cytometry is to be used in a quality-controlled environ-
ment, such as a clinical laboratory.
Our work revealed that implementation of automated
procedures for flow cytometry is time-consuming and
requires extensive testing. Automation also inevitably drives
up costs because of expensive consumables and increased
reagent use (e.g., dead-volumes in the robotic system).
Although the robotic system used in our study operated
without technical problems, we acknowledge that a certain
amount of daily and weekly maintenance was required. The
investment, however, was considered worthwhile based on
the quality of the data obtained and it is our hope that
others can benefit from the standardization of pre-analytic
approaches for sample handling. We have provided complete
access to our scripts, and encourage other Consortia to make
such procedures available to the community in order to
facilitate future improvements in the standardization of
flow cytometry procedures.
Our study was inspired by the work of H. Maecker and the
FOCIS Human Immunophenotyping Consortium, who identi-
fied technical variables in flow cytometric procedures
requiring standardization [5,6]. Here and in the accompa-
nying article [Chen et al., co-submission], we present
our efforts to optimize staining procedures, selection of
reagents, instrument set-up and data analysis. Based on the
results of extensive antibody testing (Table S1) we selected
reagents from different suppliers and thus have opted not to
use the preconfigured lyophilized reagents, as suggested by
Maecker et al. [6,15]. To rank the performance of the
antibodies of the same specificity, we assessed the staining
index and the fluorochrome stability. We observed a
significant difference in the performance of different
clones from different suppliers, results that reinforce the
need to follow MIATA guidelines [25].
Studies involving large-scale or longitudinal immuno-
phenotyping projects analyze either fresh whole blood
samples directly at the recruitment site, or PBMCs that are
separated from whole blood, frozen and shipped to the
analysis laboratory for centralized analysis. Both approaches
have advantages and inconveniences. Several studies have
275Standardized flow cytometry procedures for whole blood immunophenotypingdemonstrated that the Ficoll purification can alter the
composition and frequency of leucocyte population and the
expression of certain surface markers [6,15,26]. The
advantage of analyzing frozen PBMCs is the possibility to
perform the phenotyping of the entire cohort in the
centralized laboratory, eliminating possible errors resulting
from all preanalytical steps (reagent preparation, fluoro-
chrome stability, staining protocol, instrument set-up and
performance, etc.). We compared these two approaches by
analyzing fresh whole blood and comparing it to a portion of
the sample that was used for PBMC isolation, frozen and
later thawed for comparative analysis. Although several
markers showed no observable differences (cell number and
MFI), a considerable number of cell surface molecules were
affected by the isolation and freezing/thawing procedures.
In line with other studies, we support the use of whole blood
for immune phenotyping studies when possible.
Our gating strategy builds on the characteristics of the
new generation of cytometers that allow precise standard-
ization of the fluorescent signals (voltage-dependent set-
tings). The FSC/SSC gates that are commonly used as a first
step in gating strategy were omitted due to variance that
could not be controlled. This approach facilitated the
rational setting of gates and permitted batch-analysis using
FlowJo. As a result of these efforts, only minimal gate
positions adjustment was required for a small number of cell
populations. Additional standardization of post-analytic
gating procedures is addressed in an accompanying manu-
script [Chen et al., co-submission].
In conclusion, our efforts are in line with several
international consortia, with high coherence in the staining
protocols reported by the EuroCell Consortium [7]. These
independent approaches converge on the use of whole blood
and not frozen PBMCs, procedures for sample handling, and
criteria for reagent selection. The new generation of flow
cytometers, if properly set up and calibrated, allow precise
standardization of fluorescent signals, thus enabling reliable
results in longitudinal studies. We believe that the approach
and protocols described here provide a rational basis to
establish internationally standard operating procedures for
immunophenotying. This attention to standardized cytomet-
ric analysis is of paramount importance and will enable
inter-institutional comparative studies in healthy and dis-
eased populations.
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